Shulman Rogers’ client, Vigene, entered into an agreement with Altimmune to manufacture its single-dose intranasal vaccine candidate for COVID-19, AdCOVID™.
Commenting on the agreement, Vigene president and CEO, Dr. Zairen Sun, said, “With our new state-of-the-art manufacturing facility and our expertise in viral vector production, we are well-positioned to support Altimmune in their COVID-19 vaccine development efforts. In addition to our existing facility, we are in the process of expanding our capacity so that we can support Altimmune beyond clinical development into commercial-scale manufacturing.”
Shulman Rogers is pleased to be a part of Vigene’s growth and success and applauds their continued efforts in the war against COVID-19.
To read the full press release, click HERE.
Stay up to date with all the latest news and events.